Gilead Sciences Inc. (GILD): Price and Financial Metrics

Gilead Sciences Inc. (GILD): $77.65

1.05 (+1.37%)

POWR Rating

Component Grades








Add GILD to Watchlist
Sign Up

Industry: Biotech




#3 of 345

in industry

GILD Price/Volume Stats

Current price $77.65 52-week high $89.74
Prev. close $76.60 52-week low $72.87
Day low $76.20 Volume 5,400,400
Day high $77.66 Avg. volume 5,766,435
50-day MA $76.71 Dividend yield 4.03%
200-day MA $78.37 Market Cap 96.76B

GILD Stock Price Chart Interactive Chart >


  • Value is the dimension where GILD ranks best; there it ranks ahead of 96.18% of US stocks.
  • The strongest trend for GILD is in Growth, which has been heading up over the past 177 days.
  • GILD's current lowest rank is in the Momentum metric (where it is better than 4.01% of US stocks).

GILD Stock Summary

  • GILD has a higher market value than 97.69% of US stocks; more precisely, its current market capitalization is $94,599,500,668.
  • GILD's went public 31.83 years ago, making it older than 83.17% of listed US stocks we're tracking.
  • In terms of volatility of its share price, GILD is more volatile than merely 1.12% of stocks we're observing.
  • Stocks that are quantitatively similar to GILD, based on their financial statements, market capitalization, and price volatility, are NTES, ADI, TXN, PYPL, and BMY.
  • Visit GILD's SEC page to see the company's official filings. To visit the company's web site, go to

GILD Valuation Summary

  • GILD's price/earnings ratio is 18.5; this is 23.87% lower than that of the median Healthcare stock.
  • Over the past 243 months, GILD's price/sales ratio has gone down 11.7.

Below are key valuation metrics over time for GILD.

Stock Date P/S P/B P/E EV/EBIT
GILD 2023-11-03 3.7 4.8 18.5 14.6
GILD 2023-11-02 3.7 4.8 18.5 14.5
GILD 2023-11-01 3.6 4.7 18.2 14.4
GILD 2023-10-31 3.6 4.6 17.8 14.1
GILD 2023-10-30 3.5 4.6 17.7 14.0
GILD 2023-10-27 3.5 4.5 17.4 13.8

GILD Growth Metrics

    Its 4 year net income to common stockholders growth rate is now at -60.73%.
  • Its 5 year net cashflow from operations growth rate is now at -41.74%.
  • The 5 year net income to common stockholders growth rate now stands at -60.73%.
Over the past 34 months, GILD's revenue has gone up $4,565,000,000.

The table below shows GILD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 27,281 9,072 4,592
2022-09-30 27,136 9,710 3,334
2022-06-30 27,515 10,100 4,137
2022-03-31 27,472 10,614 4,515
2021-12-31 27,305 11,384 6,225
2021-09-30 27,482 10,095 7,394

GILD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GILD has a Quality Grade of B, ranking ahead of 89.87% of graded US stocks.
  • GILD's asset turnover comes in at 0.406 -- ranking 114th of 682 Pharmaceutical Products stocks.
  • ENTA, RDUS, and ADMS are the stocks whose asset turnover ratios are most correlated with GILD.

The table below shows GILD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.406 0.805 0.259
2021-06-30 0.402 0.801 0.179
2021-03-31 0.405 0.806 0.066
2020-12-31 0.403 0.815 0.058
2020-09-30 0.389 0.790 0.058
2020-06-30 0.375 0.786 0.009

GILD Price Target

For more insight on analysts targets of GILD, see our GILD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $75.84 Average Broker Recommendation 1.7 (Moderate Buy)

Gilead Sciences Inc. (GILD) Company Bio

Gilead Sciences Inc. is a biopharmaceutical company that discovers, develops, and commercializes new medicines in areas of unmet medical need. Its products target a number of areas, such as HIV, liver diseases, cardiovascular and other diseases. Daniel O’Day has been Gilead Science’s Chief Executive Officer since March of 2019 and the company is headquartered in Foster City, California. With over 10,000 employees worldwide, the company has operations in North America, Asia, the Middle East and Europe. As of 2019, the company had global sales of $22.1 billion. Some of Gilead Science’s major competitors are Novo Nordisk A/S ADR (NVO), Biogen Inc. (BIIB), and Novartis AG ADR (NVS).

GILD Latest News Stream

Event/Time News Detail
Loading, please wait...

GILD Latest Social Stream

Loading social stream, please wait...

View Full GILD Social Stream

Latest GILD News From Around the Web

Below are the latest news stories about GILEAD SCIENCES INC that investors may wish to consider to help them evaluate GILD as an investment opportunity.

5 Biotech Stocks Likely to Thrive as Industry Prospects Look Bright

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, CRSP, ACAD, DVAX and LGND well amid volatility.

Yahoo | November 22, 2023

The Zacks Analyst Blog Highlights Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics

Gilead Sciences, Legend Biotech, BeiGene, Exact Sciences and Sarepta Therapeutics are part of the Zacks top Analyst Blog.

Yahoo | November 21, 2023

Gilead Sciences: Breaking Barriers to Breast Cancer Care in Rural Areas

NORTHAMPTON, MA / ACCESSWIRE / November 21, 2023 / Gilead SciencesClaudia Hardy says she's found her life's mission. As director of Community Health Access and Relations for the O'Neal Comprehensive Cancer Center at the University of Alabama at Birmingham ...

Yahoo | November 21, 2023

Gilead Sciences (NASDAQ:GILD) Seems To Use Debt Quite Sensibly

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Yahoo | November 21, 2023

20 Most Valuable Healthcare Companies in the World

In this article, we will look into the 20 most valuable healthcare companies in the world. If you want to skip our detailed analysis, you can go directly to the 5 Most Valuable Healthcare Companies in the World. Healthcare Services Industry: A Market Analysis According to a report by Verified Market Research, the global healthcare […]

Yahoo | November 20, 2023

Read More 'GILD' Stories Here

GILD Price Returns

1-mo -4.41%
3-mo 2.30%
6-mo 1.86%
1-year -9.49%
3-year 44.16%
5-year 34.01%
YTD -6.91%
2022 23.63%
2021 29.95%
2020 -6.70%
2019 7.88%
2018 -9.92%

GILD Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full GILD Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!